PMC

Time course of effects of LPS and U. urealyticum alone and in combination on preterm (30 weeks) monocyte cytokine release. Preterm monocytes were incubated with medium, U. urealyticum (UU) at 10³ CCU, or LPS with or without U. urealyticum for 2 to 24 h. (A) TNF-α; (B) IL-6; (C) IL-10. Results are from a representative experiment of three experiments.

Dose-dependent effects of in vitro infection with U. urealyticum on term monocyte cytokine release. Monocytes from term cord blood were incubated with CRPMI–10% FCS alone, U. urealyticum at 10³ CCU (UU3) to 10⁶ CCU (UU6), or LPS (100 ng/ml) with or without U. urealyticum for 24 h. (A) TNF-α; (B) IL-6; (C) IL-10; (D) IL-8. Results are expressed as percentages of the LPS positive control value (mean ± SEM; n = 4). ∗, P < 0.05 versus medium control; †, P < 0.05 versus LPS.

Dose-dependent effects of in vitro infection with U. urealyticum on adult monocyte cytokine release. Monocytes from adult blood were incubated with CRPMI–10% FCS alone, U. urealyticum at 10³ CCU (UU3) to 10⁶ CCU (UU6), or LPS (100 ng/ml) with or without U. urealyticum for 24 h. (A) TNF-α; (B) IL-6; (C) IL-10; (D) IL-8. Results are expressed as percentages of the LPS positive control value (mean ± SEM; n = 6). ∗, P < 0.05 versus medium control; †, P < 0.05 versus LPS.

Comparison of cytokine release by preterm, term, and adult monocytes infected in vitro with low-inoculum U. urealyticum. Monocytes from preterm and term cord blood and adult peripheral blood were incubated with CRPMI–10% FCS medium alone, U. urealyticum (UU) at 10³ CCU (low inoculum), or LPS (100 ng/ml) with or without U. urealyticum for 24 h. (A) TNF-α; (B) IL-6; (C) IL-10; (D) IL-8. Results are expressed as percentages of the LPS positive control value (mean ± SEM; preterm n = 8, term n = 12, and adult n = 6). ∗, P < 0.05 versus LPS.

Dose-dependent effects of in vitro infection with U. urealyticum on preterm monocyte cytokine release. Monocytes from preterm cord blood (24 to 32 weeks) were incubated with CRPMI–10% FCS alone, U. urealyticum at 10³ CCU (UU3) (low inoculum) or 10⁶ CCU (UU6) (high inoculum), or LPS (100 ng/ml) with or without U. urealyticum for 24 h. (A) TNF-α; (B) IL-6; (C) IL-10; (D) IL-8. Results are expressed as percentages of the LPS positive control value (mean ± SEM; n = 6). ∗, P < 0.05 versus medium control; †, P < 0.05 versus LPS.